HOME

Scientists have discovered that lipid nanoparticles, crucial carriers for modern medicines, possess surprisingly varied internal architectures. These structural differences directly influence how effectively therapies reach their cellular destinations, according to new research.

Beyond One-Size-Fits-All: Nanoparticle Blueprints Emerge

Lipid nanoparticles (LNPs), the delivery vehicles behind groundbreaking COVID-19 vaccines and gene therapies, are far more structurally diverse than previously assumed, according to reports from a multi-institutional research collaboration. The findings, published in Nature Biotechnology, reveal that these microscopic carriers come in varied configurations that significantly impact their therapeutic performance.